非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
作者信息
Ettinger David S, Wood Douglas E, Aisner Dara L, Akerley Wallace, Bauman Jessica R, Bharat Ankit, Bruno Debora S, Chang Joe Y, Chirieac Lucian R, D'Amico Thomas A, DeCamp Malcolm, Dilling Thomas J, Dowell Jonathan, Gettinger Scott, Grotz Travis E, Gubens Matthew A, Hegde Aparna, Lackner Rudy P, Lanuti Michael, Lin Jules, Loo Billy W, Lovly Christine M, Maldonado Fabien, Massarelli Erminia, Morgensztern Daniel, Ng Thomas, Otterson Gregory A, Pacheco Jose M, Patel Sandip P, Riely Gregory J, Riess Jonathan, Schild Steven E, Shapiro Theresa A, Singh Aditi P, Stevenson James, Tam Alda, Tanvetyanon Tawee, Yanagawa Jane, Yang Stephen C, Yau Edwin, Gregory Kristina, Hughes Miranda
机构信息
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
出版信息
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
美国国立综合癌症网络（NCCN）非小细胞肺癌（NSCLC）临床实践指南为NSCLC患者提供了推荐的治疗方案，包括诊断、初始治疗、复发监测及后续治疗。符合靶向治疗或免疫治疗条件的转移性肺癌患者的生存期现在更长了。本版NCCN非小细胞肺癌指南节选重点关注转移性非小细胞肺癌患者的靶向治疗及可操作的基因突变。
Zotero 插件